REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered And Includes At Least Nitrogen And Oxygen As Ring Hetero Atoms (e.g., Monocyclic 1,2- And 1,3-oxazines, Etc.) > Morpholines (i.e., Fully Hydrogenated 1,4- Oxazines) > Additional Hetero Ring Attached Directly Or Indirectly To The Morpholine Ring By Nonionic Bonding Additional Hetero Ring Attached Directly Or Indirectly To The Morpholine Ring By Nonionic BondingAdditional Hetero Ring Attached Directly Or Indirectly To The Morpholine Ring By Nonionic Bonding patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.10/19/06 - 20060235009 - Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors The disclosure provides methods and compositions for treating a vascular, autoimmune, and/or inflammatory disease, or a condition associated therewith, with a dose of an inosine monophosphate dehydrogenase (IMPDH) inhibitor effective to treat the vascular, autoimmune and/or inflammatory disease, or associated condition but that does not produce immunosuppression sufficient to reduce ... 06/22/06 - 20060135515 - Heterocyclic amides and their use treating thromboembolic diseases and tumors Novel compounds of the formula (I), in which D, W, X, Y, T and R1 have the meaning indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours ... 01/26/06 - 20060019948 - Methylidene-d-xylopyranosyl- and oxo-d-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture wherein the groups R1 to R5, X, Z and R7a, R7b, R7c are defined as in claim 1, have an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. The present invention also relates to pharmaceutical compositions for the treatment of metabolic disorders. ... 01/12/06 - 20060009450 - Use and methods of use of etanercept and other tnf binding biologics to improve human cognitive function elivered to the interspinous or epidural space by implantable catheter, with the catheter reservoir placed remotely, such as in the abdominal area. Physical maneuvers are used to enhance delivery of etanercept to the brain via this route. In addition to etanercept there are two other non-monoclonal antibody TNF binding biologics ... 12/08/05 - 20050272727 - Leptomycin compounds wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity. ... ### FreshPatents.com Support |